Pharmacokinetics of bevacizumab after topical and intravitreal administration in human eyes.
about
Clinical use of Bevacizumab in treating refractory glaucomaEFFICACY OF INTRAVITREAL AFLIBERCEPT IN MACULAR TELANGIECTASIA TYPE 1 IS LINKED TO THE OCULAR ANGIOGENIC PROFILE.Long-term outcomes of intravitreal injection of bevacizumab for choroidal neovascularization associated with choroidal osteoma.Efficacy and safety of different doses of a slow-release corticosteroid implant for macular edema: meta-analysis of randomized controlled trialsSystemic and Intravitreal Delivery of Dendrimers to Activated Microglia/Macrophage in Ischemia/Reperfusion Mouse Retina.Ziv-aflibercept in macular disease.Effects of intravitreal ranibizumab on the untreated eye and systemic gene expression profile in age-related macular degeneration.Sustained-release corticosteroid options.Recent perspectives on the delivery of biologics to back of the eye.Use of Anti-VEGF Agents in Glaucoma Surgery.Three-year corneal graft survival rate in high-risk cases treated with subconjunctival and topical bevacizumab.Management of macular edema secondary to branch retinal vein occlusion in an eye with prior vitrectomy and lensectomyComparative Study of In Situ Loaded Antibody and PEG-Fab NIPAAM Gels.Pharmacokinetics of intravitreal anti-VEGF drugs in vitrectomized versus non-vitrectomized eyes.Ocular delivery of proteins and peptides: challenges and novel formulation approaches.Comparison of the Effect of Intravitreal Dexamethasone Implant in Vitrectomized and Nonvitrectomized Eyes for the Treatment of Diabetic Macular Edema.Extended Intravitreal Rabbit Eye Residence of Nanoparticles Conjugated With Cationic Arginine Peptides for Intraocular Drug Delivery: In Vivo Imaging
P2860
Q28083405-6A8628FA-2B6F-40B0-811E-FABA64227482Q30490563-543D6D15-CE22-4E3E-9ACC-8324EF6860C7Q35168693-ACF046A1-36A3-4212-AC0A-BE0F0D39FFA2Q35594036-6543CA98-D71F-4588-89BB-E5BB05290861Q35877208-B583C297-65DC-45C7-B7DE-D81C382A36FCQ35899591-496DEA72-26FB-4302-AA56-119818D58D16Q36757415-42DD3C4B-17ED-4134-A5B1-AE407D26CE03Q38241548-3C8AEE3A-EAB0-4356-AB42-46030EBD6123Q38940171-1E54F494-3B22-485E-BEF6-73E5AB8C8516Q41320402-B775FBAC-7F93-42D3-82F0-3164796F21E0Q41660636-B34EAAAE-9A98-44C8-94E4-35A6A08928A4Q42116625-EB390064-94F0-4B55-8F70-6C8F2E4423A1Q47330134-CA660B94-43E4-414E-ADB6-938AE007EEB8Q47405816-81D88CF8-B14C-42D9-A94D-3C031CB8F53EQ47729137-D4FCF981-EC58-4560-85FA-AEA908DD8E78Q55116052-8C4FFD43-0DF4-4937-874E-5140E69CCCA7Q58806008-078381D4-DD06-44F4-B244-772BFE7935F5
P2860
Pharmacokinetics of bevacizumab after topical and intravitreal administration in human eyes.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 31 October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pharmacokinetics of bevacizuma ...... administration in human eyes.
@en
Pharmacokinetics of bevacizuma ...... administration in human eyes.
@nl
type
label
Pharmacokinetics of bevacizuma ...... administration in human eyes.
@en
Pharmacokinetics of bevacizuma ...... administration in human eyes.
@nl
prefLabel
Pharmacokinetics of bevacizuma ...... administration in human eyes.
@en
Pharmacokinetics of bevacizuma ...... administration in human eyes.
@nl
P2093
P2860
P1476
Pharmacokinetics of bevacizuma ...... administration in human eyes.
@en
P2093
Adiel Barak
Anat Loewenstein
Elad Ben-Artsi
Elad Moisseiev
Eliya Levinger
Irina S Barequet
Karl Csaky
Michael Waisbourd
Tad Daniels
P2860
P2888
P304
P356
10.1007/S00417-013-2495-0
P577
2013-10-31T00:00:00Z